Bioprinter manufacturer REGEMAT3D is launching a new equity crowdfunding round, that will help the company further scale its business and product lines while preparing for an IPO set to take place in 2023. At 3dpbm we usually do not cover crowdfunding campaigns for new products, however, this initiative is relative to a company that is already present in the market and has been making significant progress in the bioprinting segment. REGEMAT3D promises massive returns (up to 3 to 4 times the investment) and while the actual success of this financial initiative is subject to the same risks as any financial venture, the overall bioprinting segment is in fact growing up rapidly.
There are many reasons supporting the growth of the bioprinting industry. One is that the best investment in life is health. And certainly today and despite the recent pandemic, quality of life standards are much higher than in previous times. We have never lived so much or better. Although we are still victims of hundreds of types of diseases, including all those derived from aging.
To solve it, a large number of researchers work in laboratories around the world to find solutions to diseases and develop technologies and treatments that achieve it. Among them, the emerging biofabrication industry is positioned as one of the main ones, with 3D bioprinting being one of the most promising. These technologies aim to manufacture tissues and organs in the laboratory so that lesions can regenerate and shorten donor waiting lists.
REGEMAT3D, based in Granada, is one of the main players in this new industry. The company manufactures tissue and organ biofabrication systems – bioprinters and bioreactors – that researchers around the world use to try to find solutions to tissue damage in tissues such as cartilage, bone, spinal cord and muscle tissue among others. They currently have a presence in 29 countries.
According to independent studies, the biofabrication market will reach 1,647 million dollars in 2024, with the research market mainly being the main driver of these figures. The company believes that in the coming years we will begin to see solutions based on bioprinting in the clinic, for this, it is necessary to increase the resources allocated to these technologies.
At the end of 2020, REGEMAT carried out a crowdfunding round that has served to increase its turnover, release a new bioprinter, the REG4LIfe, and set up a patented bioreactor to manufacture articular cartilage. Now they are preparing the next one which will drive them with the objective of an IPO in the coming years.
The company has also launched the Labmethods.com platform, as the bioprinting “Thingiverse”, where researchers from all over the world will share their methods of biomanufacturing tissues in a way that accelerates the development of solutions in the area. “It is like a recipe website where researchers find descriptions of how to make a specific tissue, and they can access to buy all the necessary ingredients easily and quickly. If you want to do something and part of the work is already done, why waste time with this? I go to a recipe and focus my efforts on another facet of the research, so together we get to have the results beforehand ” told us José Manuel Baena, PhD in biomedicine and founder of the company.
The enormous number of tissue pathologies derived from aging and the need to accelerate the development of new drugs and reduce the use of animals for research makes 3D bioprinting a sector that is gaining much interest in the research and scientific field, who see these technologies as an enhancer to achieve future solutions that can be taken to the clinical field.